𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Growth-regulatory mechanism of two human esophageal-cancer cell lines in protein-free conditions

✍ Scribed by K. Iihara; H. Shiozaki; K. Oku; H. Tahara; Y. Doki; H. Oka; T. Kadowaki; T. Iwazawa; M. Inouh; T. Mori


Publisher
John Wiley and Sons
Year
1993
Tongue
French
Weight
778 KB
Volume
55
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


We investigated the growth-regulatory mechanism of 2 esophageal squatnous-cancer cell lines, TE2-NS and TE3-0s cells, both of which can grow stably in protein-free conditions in vitro. Protein-free conditioned media from TE2-NS and TE3-OS cells stimulated the growth of these cells. Exogenous epidermal growth factor (EGF), transforming growth factor-alpha (TGFa), insulin-like growth factor (IGF)-I and -11 enhanced cell proliferation by 2.2-to 3.8-fold in protein-free conditions, as compared with an untreated control. Receptor-binding assays showed that both TE2-NS and TE3-OS cells possessed a single class of high-affinity binding sites for IGF-I and 2 classes of binding sites for TGF-a, as confirmed on the cell membrane by immunochemistry. These results suggest that EGF, TGF-a and IGFs are candidates for the autocrine growth factor in cancer cells. The addition of inhibitory monoclonal antibodies against TGF-a and EGFR, but not those against either EGF or IGF-IR. significantly inhibited growth of the cells. lmmunocytochemical staining and ELISA of the conditioned media both confirmed the production of TGF-a protein, but not EGF protein, in these cell lines. The data for a protein-free culture system strongly suggested that TGF-a, but not EGF or IGF, is biologically important as an autocrine growth factor in the growth of these cell lines in vitro.


📜 SIMILAR VOLUMES


Inactivation of the p53 protein in cell
✍ Christoph Barnas; Ghyslaine Martel-Planche; Yoichi Furukawa; Monica Hollstein; R 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 225 KB 👁 2 views

Alteration of the p53 gene is thought to be important in the early stages of human esophageal cancers, but how this confers a selective advantage to esophageal cancer cells is unknown. In this report, we analyzed 9 cell lines derived from human esophageal cancers (TE-1, TE-3, TE-6, TE-7, TE-9, TE-10

Characterization of DNA demethylation in
✍ Mariappan Vairapandi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB 👁 1 views

## Abstract DNA methylation/demethylation constitutes a major consequence in all biological processes involving transcription, differentiation, development, DNA repair, recombination, and chromosome organization. Our earlier studies established that demethylation of CpG rich sequence by human DNA d

Secretion and biological actions of insu
✍ Cecilia Camacho-Hubner; Robert H. McCusker; David R. Clemmons 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 1017 KB

The insulin-like growth factors (IGFs) I and II are present in extracellular fluids associated with specific binding proteins (IGFBPs) that can modify their biologic actions. These studies were undertaken to determine which forms of IGFBP are secreted by endometrial carcinoma (HEC-1 B) and breast ca

Bone extracellular matrix induces homeob
✍ Robbins, Steven E.; Shu, Wei-Ping; Kirschenbaum, Alexander; Levine, Alice C.; Mi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 747 KB

## BACKGROUND. Differences in gene expression in prostate cells are believed to be secondary to epithelial-stromal interactions. We theorized that bone matrix may provide a fertile "soil" for prostate cancer by inducing androgen-dependent genes and allowing for androgen-independent growth. METHODS

CCAAT/enhancer binding protein δ (C/EBPδ
✍ G.S. Sivko; J.W. DeWille 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

## Abstract “Loss of function” alterations in growth inhibitory signal transduction pathways are common in cancer cells. In this study, we show that growth arrest (GA) treatments—serum and growth factor withdrawal and growth inhibitory IL‐6 family cytokines (Interleukin‐6 and Oncostatin M (OSM))—in